1. Home
  2. APPF vs BLTE Comparison

APPF vs BLTE Comparison

Compare APPF & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AppFolio Inc.

APPF

AppFolio Inc.

HOLD

Current Price

$169.90

Market Cap

5.6B

Sector

Technology

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$160.80

Market Cap

6.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APPF
BLTE
Founded
2006
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.6B
6.6B
IPO Year
2015
2021

Fundamental Metrics

Financial Performance
Metric
APPF
BLTE
Price
$169.90
$160.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
7
Target Price
$286.33
$198.00
AVG Volume (30 Days)
282.5K
133.2K
Earning Date
04-23-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.18
N/A
Revenue
$950,822,000.00
N/A
Revenue This Year
$19.69
N/A
Revenue Next Year
$16.70
$492.11
P/E Ratio
$128.42
N/A
Revenue Growth
19.72
N/A
52 Week Low
$142.73
$56.68
52 Week High
$325.90
$200.00

Technical Indicators

Market Signals
Indicator
APPF
BLTE
Relative Strength Index (RSI) 58.30 44.01
Support Level $161.13 $157.63
Resistance Level $191.16 $161.28
Average True Range (ATR) 6.56 7.07
MACD 2.18 -0.59
Stochastic Oscillator 76.91 10.75

Price Performance

Historical Comparison
APPF
BLTE

About APPF AppFolio Inc.

AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: